TITLE

Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial

AUTHOR(S)
Clement, A.; Tamalet, A.; Leroux, E.; Ravilly, S.; Fauroux, B.; Jais, J.-P.
PUB. DATE
October 2006
SOURCE
Thorax;Oct2006, Vol. 61 Issue 10, p895
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Macrolides display immunomodulatory effects that may be beneficial in chronic inflammatory pulmonary diseases. The aim of the study was to document whether long term use of azithromycin may be associated with respiratory benefits in young patients with cystic fibrosis. Methods: A multicentre, randomised, double blind, placebo controlled trial was conducted from October 2001 to June 2003. The criteria for enrolment were age older than 6 years and forced expiratory volume in 1 second (FEV1) of 40% or more. The active group received either 250 mg or 500 mg (body weight < or ~40 kg) of oral azithromycin three times a week for 12 months. The primary end point was change in FEV1. Results: Eighty two patients of mean (SD) age 11.0 (3.3) years and mean (SD) FEV1 85 (22)% predicted were randomised: 40 in the azithromycin group and 42 in the placebo group. Nineteen patients were infected with Pseudomonas aeruginosa. The relative change in FEV1 at month 12 did not differ significantly between the two groups. The number of pulmonary exacerbations (count ratio 0.50 (95% CI 0.32 to 0.79), p<0.005), the time elapsed before the first pulmonary exacerbation (hazard ratio 0.37 (95% CI 0.22 to 0.63), p<0.0001), and the number of additional courses of oral antibiotics were significantly reduced in the azithromycin group regardless of the infectious status (count ratio 0.55 (95% CI 0.36 to 0.85), p<0.01). No severe adverse events were reported. Conclusion: Long term use of low dose azithromycin in young patients with cystic fibrosis has a beneficial effect on lung disease expression, even before infection with Pseudomonas aeruginosa.
ACCESSION #
22926537

 

Related Articles

  • Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. Yun Cai; Dong Chai; Rui Wang; Nan Bai; Bei-Bei Liang; Youning Liu // Journal of Antimicrobial Chemotherapy (JAC);May2011, Vol. 66 Issue 5, p968 

    Objectives To evaluate the efficacy and safety of macrolides in cystic fibrosis (CF). Methods Randomized controlled trials (RCTs) of macrolides for the treatment of CF published in PubMed, the Cochrane Library and Embase were searched. Application of inclusion and exclusion criteria, data...

  • CITATIONS AND CLINICIANS' NOTES: CYSTIC FIBROSIS.  // Current Medical Literature: Respiratory Medicine;2004, Vol. 18 Issue 1, p26 

    Presents citations and clinicians' notes on studies on cystic fibrosis. "Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL," by N. Reinhardt, et al; "Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease,"...

  • Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? Kazuhiro Tateda; Yoshikazu Ishii; Soichiro Kimura; Manabu Horikawa; Shinichi Miyairi; Keizo Yamaguchi // Journal of Infection & Chemotherapy (Springer Science & Business;Dec2007, Vol. 13 Issue 6, p357 

    Abstract  A breakthrough in antibiotic chemotherapy for patients with chronic Pseudomonas aeruginosa pulmonary infections was brought about by findings in a patient with diffuse panbronchiolitis (DPB), who had been treated with erythromycin over a period of years. Recent clinical trials...

  • Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Wolter, J.; Seeney, S.; Bell, S.; Bowler, S.; Masel, P.; McCormack, J. // Thorax;Mar2002, Vol. 57 Issue 3, p212 

    Background: Relentless chronic pulmonary inflammation is the major contributor to morbidity and mortality in patients with cystic fibrosis (CF). While immunomodulating therapies such as prednisolone and ibuprofen may be beneficial, their use is limited by side effects. Macrolides have...

  • Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa. Saiman, Lisa; Anstead, Michael; Mayer-Hamblett, Nicole; Lands, Larry C.; Kloster, Margaret; Hocevar-Trnka, Jasna; Goss, Christopher H.; Rose, Lynn M.; Burns, Jane L.; Marshall, Bruce C.; Ratjen, Felix // JAMA: Journal of the American Medical Association;5/5/2010, Vol. 303 Issue 17, p1707 

    The article discusses a study which investigated the link between azithromycin treatment and an improvement in lung function and a reduction in pulmonary exacerbations in pediatric cystic fibrosis (CF) patients uninfected with Pseudomonas aeruginosa. The researchers conducted a multicenter,...

  • Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. Lutz, Larissa; Castro Pereira, Dariane; Minuto Paiva, Rodrigo; Prehn Zavascki, Alexandre; Luis Barth, Afonso // BMC Microbiology;2012, Vol. 12 Issue 1, p196 

    Background: Biofilm production is an important mechanism for bacterial survival and its association with antimicrobial resistance represents a challenge for the patient treatment. In this study we evaluated the in vitro action of macrolides in combination with anti-pseudomonal agents on...

  • Cystic Fibrosis (CF), Pseudomonas aeruginosa, CFTR and the CF Glycosylation Phenotype: A Review and Update. Stoykova, L. I.; Scanlin, T. F. // Current Organic Chemistry;Jul2008, Vol. 12 Issue 11, p900 

    Cystic Fibrosis (CF) is a common, ultimately fatal, inherited disorder of exocrine glands. The dominant clinical feature is a chronic progressive lung disease mediated by airways infection and inflammation. The most important pathogen in the lungs is Pseudomonas aeruginosa (P. aeruginosa)....

  • Pseudomonas siderophores in the sputum of patients with cystic fibrosis. Martin, Lois; Reid, David; Sharples, Katrina; Lamont, Iain // BioMetals;Dec2011, Vol. 24 Issue 6, p1059 

    The lungs of patients with cystic fibrosis become chronically infected with the bacterium Pseudomonas aeruginosa, which heralds progressive lung damage and a decline in health. Iron is a crucial micronutrient for bacteria and its acquisition is a key factor in infection. P. aeruginosa can...

  • Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis. Le Gall, Florence; Le Berre, Rozenn; Rosec, Sylvain; Hardy, Jeanne; Gouriou, Stéphanie; Boisramé-Gastrin, Sylvie; Vallet, Sophie; Rault, Gilles; Payan, Christopher; Héry-Arnaud, Geneviève // BMC Microbiology;2013, Vol. 13 Issue 1, p1 

    Background: The lung of patients with cystic fibrosis (CF) is particularly sensitive to Pseudomonas aeruginosa. This bacterium plays an important role in the poor outcome of CF patients. During the disease progress, first acquisition of P. aeruginosa is the key-step in the management of CF...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics